TGTX Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of 4.19% compared to TG Therapeutics's net margin of -55.52%. TG Therapeutics's return on equity of 19.78% beat Ardelyx's return on equity of -34.68%.

TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 13.53%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 156.02%. Given that Ardelyx has higher upside potential than TG Therapeutics, analysts believe Ardelyx is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than Ardelyx quarterly revenues of $74.1M. TG Therapeutics's net income of $5.1M is higher than Ardelyx's net income of -$41.1M. Notably, TG Therapeutics's price-to-earnings ratio is 151.21x while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.10x versus 2.74x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of 4.19% compared to TG Therapeutics's net margin of 0.33%. TG Therapeutics's return on equity of 19.78% beat Blueprint Medicines's return on equity of -49.13%.

TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 13.53%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.04%. Given that TG Therapeutics has higher upside potential than Blueprint Medicines, analysts believe TG Therapeutics is more attractive than Blueprint Medicines.

TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. TG Therapeutics's net income of $5.1M is higher than Blueprint Medicines's net income of $496K. Notably, TG Therapeutics's price-to-earnings ratio is 151.21x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.10x versus 14.62x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of 4.19% compared to TG Therapeutics's net margin of -74.86%. TG Therapeutics's return on equity of 19.78% beat AVITA Medical's return on equity of -415.55%.

TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 13.53%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 227.57%. Given that AVITA Medical has higher upside potential than TG Therapeutics, analysts believe AVITA Medical is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than AVITA Medical quarterly revenues of $18.5M. TG Therapeutics's net income of $5.1M is higher than AVITA Medical's net income of -$13.9M. Notably, TG Therapeutics's price-to-earnings ratio is 151.21x while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.10x versus 1.87x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 4.19% compared to TG Therapeutics's net margin of -151.35%. TG Therapeutics's return on equity of 19.78% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 13.53%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 24.65%. Given that Rhythm Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 1.913, which suggesting that the stock is 91.257% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.265, suggesting its more volatile than the S&P 500 by 126.541%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $120.9M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. TG Therapeutics's net income of $5.1M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, TG Therapeutics's price-to-earnings ratio is 151.21x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 15.10x versus 30.18x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.